141 related articles for article (PubMed ID: 24890746)
1. Medical eligibility, contraceptive choice, and intrauterine device acceptance among HIV-infected women receiving antiretroviral therapy in Lilongwe, Malawi.
Haddad LB; Feldacker C; Jamieson DJ; Tweya H; Cwiak C; Bryant AG; Hosseinipour MC; Chaweza T; Mlundira L; Kachale F; Stuart GS; Hoffman I; Phiri S
Int J Gynaecol Obstet; 2014 Sep; 126(3):213-6. PubMed ID: 24890746
[TBL] [Abstract][Full Text] [Related]
2. Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate.
Haddad LB; Cwiak C; Jamieson DJ; Feldacker C; Tweya H; Hosseinipour M; Hoffman I; Bryant AG; Stuart GS; Noah I; Mulundila L; Samala B; Mayne P; Phiri S
Contraception; 2013 Dec; 88(6):737-43. PubMed ID: 24060297
[TBL] [Abstract][Full Text] [Related]
3. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
4. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
Morrison CS; Hofmeyr GJ; Thomas KK; Rees H; Philip N; Palanee-Phillips T; Nanda K; Nair G; Onono M; Mastro TD; Lind M; Heffron R; Edward V; Deese J; Beksinska M; Beesham I; Stringer JSA; Baeten JM; Ahmed K;
AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
[TBL] [Abstract][Full Text] [Related]
5. Familiarity and acceptability of long-acting reversible contraception and contraceptive choice.
Paul R; Huysman BC; Maddipati R; Madden T
Am J Obstet Gynecol; 2020 Apr; 222(4S):S884.e1-S884.e9. PubMed ID: 31838124
[TBL] [Abstract][Full Text] [Related]
6. Integrating reproductive health services into HIV care: strategies for successful implementation in a low-resource HIV clinic in Lilongwe, Malawi.
Phiri S; Feldacker C; Chaweza T; Mlundira L; Tweya H; Speight C; Samala B; Kachale F; Umpierrez D; Haddad L;
J Fam Plann Reprod Health Care; 2016 Jan; 42(1):17-23. PubMed ID: 25902815
[TBL] [Abstract][Full Text] [Related]
7. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
[TBL] [Abstract][Full Text] [Related]
8. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
9. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial.
Stringer EM; Levy J; Sinkala M; Chi BH; Matongo I; Chintu N; Stringer JS
AIDS; 2009 Jul; 23(11):1377-82. PubMed ID: 19448528
[TBL] [Abstract][Full Text] [Related]
10. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
[TBL] [Abstract][Full Text] [Related]
11. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
[TBL] [Abstract][Full Text] [Related]
12. Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi.
Zia Y; Tang JH; Chinula L; Tegha G; Stanczyk FZ; Kourtis AP
Contraception; 2019 Nov; 100(5):402-405. PubMed ID: 31374188
[TBL] [Abstract][Full Text] [Related]
13. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
Hubacher D; Spector H; Monteith C; Chen PL; Hart C
Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
[TBL] [Abstract][Full Text] [Related]
14. Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection.
Tepper NK; Curtis KM; Cox S; Whiteman MK
MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(14):405-410. PubMed ID: 32271729
[TBL] [Abstract][Full Text] [Related]
15. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
Haddad LB; Tang JH; Davis NL; Kourtis AP; Chinula L; Msika A; Tegha G; Hosseinipour MC; Nelson JAE; Hobbs MM; Gajer P; Ravel J; De Paris K
mSphere; 2023 Feb; 8(1):e0058522. PubMed ID: 36622252
[TBL] [Abstract][Full Text] [Related]
16. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
[TBL] [Abstract][Full Text] [Related]
17. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
Hofmeyr GJ; Singata-Madliki M; Lawrie TA; Bergel E; Temmerman M
Reprod Health; 2016 Apr; 13():42. PubMed ID: 27091008
[TBL] [Abstract][Full Text] [Related]
18. Contraceptive use and pregnancy rates among women receiving antiretroviral therapy in Malawi: a retrospective cohort study.
Tweya H; Feldacker C; Gugsa S; Phiri S
Reprod Health; 2018 Feb; 15(1):25. PubMed ID: 29426333
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.
Kourtis AP; Haddad L; Tang J; Chinula L; Hurst S; Wiener J; Ellington S; Nelson JA; Corbett A; De Paris K; King CC; Hosseinipour M; Hoffman IF; Jamieson DJ
Contemp Clin Trials; 2017 Jan; 52():27-34. PubMed ID: 27836505
[TBL] [Abstract][Full Text] [Related]
20. Canadian Contraception Consensus (Part 2 of 4).
Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
